About this trial
Skin donor sites in patients undergoing split-thickness skin grafting surgeries can be very painful postoperatively. This site is most often the anterolateral thigh, the pain at which location can traditionally be covered by a fascia iliaca nerve block, although that comes with the disadvantage of losing motor functions in the femoral nerve distribution. The LAM nerve block, which is relatively new, aims to provide analgesia in the distribution of the lateral and anterior femoral cutaneous nerves. In short, this nerve block would decrease the sensation of the anterolateral thigh area without affecting the motor function of the leg. Investigators aim to study the consistency and coverage size of sensation changes by mapping out the area after the block in each patient.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years or older
Scheduled surgery for STSG w/ donor site coming from thigh
Care team requests LAM nerve block
Anticipated postop pain in the cutaneous areas of anterior and lateral thigh
Disqualifiers
Inability to communicate sensation or motor changes in their body
Preexisting sensory or motor deficits in the femoral nerve distribution
Contraindication to the medication used or a peripheral nerve block, such as allergy to amide local anesthetics, severe liver dysfunction, injection site infection etc
Pregnancy
Trial population
Patients 18 years or older who are undergoing skin grafting surgeries
Trial design
Case-only
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Area of sensory change after nerve block
Sponsors and contacts
Click on the lead sponsor to view all of their trials.